Immuno Chemistry Market Outlook in BRICS (Brazil, Russia, India, China, South Africa) to 2017

Report Summary

GlobalData’s new report, “Immuno Chemistry Market Outlook in BRICS (Brazil, Russia, India, China, South Africa) to 2017” provides key market data on the Immuno Chemistry market in the BRICS countries. The report provides value ($m) data for each segment and sub-segment within nine market categories – Disease Specific Immunochemistry, Endocrinology Tests, Immunochemistry Rapid Tests, Immunochemistry Analyzers, Organ Function Assays, Anemia / Vitamin Tests, Therapeutic Drug Monitoring, Specific Proteins and Drugs of Abuse / Toxicology. The report also provides company shares and distribution shares data for the overall Immuno Chemistry market in each of the aforementioned countries. The report is also supplemented with global corporate-level profiles of the key market participants with information on key developments, wherever available.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

The emerging economies, comprising China, India, Brazil, Russia and South Africa, with a significantly large pool of under-served patients, represent the next big opportunity for the leading medical equipment and devices manufacturers. China remains the world’s most populous country and is consequently home to a large patient base. The country is home to more than 120 million people who are aged 65 or older—a population in continuous need of medical care. India, the second most populous country globally, is home to 1.2 billion people, approximately 5% of which are aged 65 or older. It’s estimated that shortly after 2020, India’s population will surpass China, making it the most populous country in the world. As the population continues to grow and people continue to age, the underlying demand for healthcare is also expected to increase.

Scope

• Market size data for Immuno Chemistry market categories – Disease Specific Immunochemistry, Endocrinology Tests, Immunochemistry Rapid Tests, Immunochemistry Analyzers, Organ Function Assays, Anemia / Vitamin Tests, Therapeutic Drug Monitoring, Specific Proteins and Drugs of Abuse / Toxicology.
• Annualized market revenues ($m) data for each of the segments and sub-segments within the nine market categories. Data from 2003 to 2010, forecast forward for seven years to 2017.
• 2010 company shares and distribution shares data for the overall Immuno Chemistry market in each of the aforementioned countries.
• Global corporate-level profiles of key companies operating within the Immuno Chemistry market in BRICS.
• Key players covered include Siemens Healthcare, F. Hoffmann-La Roche Ltd., Abbott Laboratories, Ortho-Clinical Diagnostics Inc., Beckman Coulter, Inc., bioMerieux S.A., Phadia AB, Alere Inc., Bio-Rad Laboratories, Inc., Transasia Bio-Medicals Ltd. and DiaSorin S.p.A.

Reasons to buy

• Develop business strategies by identifying the key market categories and segments poised for strong growth.
• Develop market-entry and market expansion strategies.
• Design competition strategies by identifying who-stands-where in the Immuno Chemistry competitive landscape in BRICS.
• Develop capital investment strategies by identifying the key market segments expected to register strong growth in the near future.
• What are the key distribution channels and what’s the most preferred mode of product distribution – Identify, understand and capitalize.

Table of Contents

1 Table of Contents 2
1.1 List of Tables 8
1.2 List of Figures 12

2 Introduction 16
2.1 What Is This Report About? 16

3 Immuno Chemistry in BRICS 17
3.1 Immuno Chemistry, BRICS, Overall Revenue ($m), 2003-2017 17
3.2 Immuno Chemistry, BRICS, Company share (2009-2010) 23

4 Immuno Chemistry In Brazil 25
4.1 Immuno Chemistry, Brazil, Overall Revenue ($m), USD Actual, 2003-2017 25
4.2 Disease Specific Immunochemistry In Brazil 31
4.2.1 Disease Specific Immunochemistry, Brazil, Overall Revenue (2003-2017) 31
4.3 Endocrinology Tests In Brazil 35
4.3.1 Endocrinology Tests, Brazil, Overall Revenue (2003-2017) 35
4.4 Organ Function Assays In Brazil 38
4.4.1 Organ Function Assays, Brazil, Overall Revenue (2003-2017) 38
4.5 Therapeutic Drug Monitoring In Brazil 40
4.5.1 Therapeutic Drug Monitoring, Brazil, Overall Revenue (2003-2017) 40
4.6 Immunochemistry Analyzers In Brazil 44
4.6.1 Immunochemistry Analyzers, Brazil, Overall Revenue (2003-2017) 44
4.7 Specific Proteins In Brazil 48
4.7.1 Specific Proteins, Brazil, Overall Revenue (2003-2017) 48
4.8 Anemia / Vitamin Tests In Brazil 50
4.8.1 Anemia / Vitamin Tests, Brazil, Overall Revenue (2003-2017) 50
4.9 Immunochemistry Rapid Tests In Brazil 52
4.9.1 Immunochemistry Rapid Tests, Brazil, Overall Revenue (2003-2017) 52
4.10 Drugs of Abuse / Toxicology In Brazil 54
4.10.1 Drugs of Abuse / Toxicology, Brazil, Overall Revenue (2003-2017) 54
4.11 Immuno Chemistry, Brazil, Distribution Share (2009-2010) 58
4.12 Immuno Chemistry, Brazil, Company Share (2009-2010) 59

5 Immuno Chemistry In Russian Federation 61
5.1 Immuno Chemistry, Russian Federation, Overall Revenue ($m), USD Actual, 2003-2017 61
5.2 Immunochemistry Analyzers In Russian Federation 67
5.2.1 Immunochemistry Analyzers, Russian Federation, Overall Revenue (2003-2017) 67
5.3 Endocrinology Tests In Russian Federation 71
5.3.1 Endocrinology Tests, Russian Federation, Overall Revenue (2003-2017) 71
5.4 Disease Specific Immunochemistry In Russian Federation 75
5.4.1 Disease Specific Immunochemistry, Russian Federation, Overall Revenue (2003-2017) 75
5.5 Organ Function Assays In Russian Federation 79
5.5.1 Organ Function Assays, Russian Federation, Overall Revenue (2003-2017) 79
5.6 Anemia / Vitamin Tests In Russian Federation 81
5.6.1 Anemia / Vitamin Tests, Russian Federation, Overall Revenue (2003-2017) 81
5.7 Specific Proteins In Russian Federation 83
5.7.1 Specific Proteins, Russian Federation, Overall Revenue (2003-2017) 83
5.8 Therapeutic Drug Monitoring In Russian Federation 85
5.8.1 Therapeutic Drug Monitoring, Russian Federation, Overall Revenue (2003-2017) 85
5.9 Drugs of Abuse / Toxicology In Russian Federation 89
5.9.1 Drugs of Abuse / Toxicology, Russian Federation, Overall Revenue (2003-2017) 89
5.10 Immunochemistry Rapid Tests In Russian Federation 93
5.10.1 Immunochemistry Rapid Tests, Russian Federation, Overall Revenue (2003-2017) 93
5.11 Immuno Chemistry, Russian Federation, Distribution Share (2009-2010) 95
5.12 Immuno Chemistry, Russian Federation, Company Share (2009-2010) 96

6 Immuno Chemistry In India 98
6.1 Immuno Chemistry, India, Overall Revenue ($m), USD Actual, 2003-2017 98
6.2 Endocrinology Tests In India 104
6.2.1 Endocrinology Tests, India, Overall Revenue (2003-2017) 104
6.3 Immunochemistry Rapid Tests In India 108
6.3.1 Immunochemistry Rapid Tests, India, Overall Revenue (2003-2017) 108
6.4 Immunochemistry Analyzers In India 110
6.4.1 Immunochemistry Analyzers, India, Overall Revenue (2003-2017) 110
6.5 Disease Specific Immunochemistry In India 114
6.5.1 Disease Specific Immunochemistry, India, Overall Revenue (2003-2017) 114
6.6 Organ Function Assays In India 118
6.6.1 Organ Function Assays, India, Overall Revenue (2003-2017) 118
6.7 Anemia / Vitamin Tests In India 120
6.7.1 Anemia / Vitamin Tests, India, Overall Revenue (2003-2017) 120
6.8 Drugs of Abuse / Toxicology In India 122
6.8.1 Drugs of Abuse / Toxicology, India, Overall Revenue (2003-2017) 122
6.9 Specific Proteins In India 126
6.9.1 Specific Proteins, India, Overall Revenue (2003-2017) 126
6.10 Therapeutic Drug Monitoring In India 128
6.10.1 Therapeutic Drug Monitoring, India, Overall Revenue (2003-2017) 128
6.11 Immuno Chemistry, India, Distribution Share (2009-2010) 132
6.12 Immuno Chemistry, India, Company Share (2009-2010) 133

7 Immuno Chemistry In China 135
7.1.1 Immuno Chemistry, China, Overall Revenue ($m), USD Actual, 2003-2017 135
7.2 Disease Specific Immunochemistry In China 141
7.2.1 Disease Specific Immunochemistry, China, Overall Revenue (2003-2017) 141
7.3 Immunochemistry Rapid Tests In China 145
7.3.1 Immunochemistry Rapid Tests, China, Overall Revenue (2003-2017) 145
7.4 Endocrinology Tests In China 147
7.4.1 Endocrinology Tests, China, Overall Revenue (2003-2017) 147
7.5 Immunochemistry Analyzers In China 151
7.5.1 Immunochemistry Analyzers, China, Overall Revenue (2003-2017) 151
7.6 Organ Function Assays In China 155
7.6.1 Organ Function Assays, China, Overall Revenue (2003-2017) 155
7.7 Anemia / Vitamin Tests In China 157
7.7.1 Anemia / Vitamin Tests, China, Overall Revenue (2003-2017) 157
7.8 Specific Proteins In China 159
7.8.1 Specific Proteins, China, Overall Revenue (2003-2017) 159
7.9 Therapeutic Drug Monitoring In China 161
7.9.1 Therapeutic Drug Monitoring, China, Overall Revenue (2003-2017) 161
7.10 Drugs of Abuse / Toxicology In China 165
7.10.1 Drugs of Abuse / Toxicology, China, Overall Revenue (2003-2017) 165
7.11 Immuno Chemistry, China, Distribution Share (2009-2010) 169
7.12 Immuno Chemistry, China, Company Share (2009-2010) 170

8 Immuno Chemistry In South Africa 172
8.1 Immuno Chemistry, South Africa, Overall Revenue ($m), USD Actual, 2003-2017 172
8.2 Disease Specific Immunochemistry In South Africa 178
8.2.1 Disease Specific Immunochemistry, South Africa, Overall Revenue (2003-2017) 178
8.3 Immunochemistry Analyzers In South Africa 182
8.3.1 Immunochemistry Analyzers, South Africa, Overall Revenue (2003-2017) 182
8.4 Organ Function Assays In South Africa 186
8.4.1 Organ Function Assays, South Africa, Overall Revenue (2003-2017) 186
8.5 Endocrinology Tests In South Africa 188
8.5.1 Endocrinology Tests, South Africa, Overall Revenue (2003-2017) 188
8.6 Immunochemistry Rapid Tests In South Africa 192
8.6.1 Immunochemistry Rapid Tests, South Africa, Overall Revenue (2003-2017) 192
8.7 Specific Proteins In South Africa 194
8.7.1 Specific Proteins, South Africa, Overall Revenue (2003-2017) 194
8.8 Therapeutic Drug Monitoring In South Africa 196
8.8.1 Therapeutic Drug Monitoring, South Africa, Overall Revenue (2003-2017) 196
8.9 Anemia / Vitamin Tests In South Africa 200
8.9.1 Anemia / Vitamin Tests, South Africa, Overall Revenue (2003-2017) 200
8.10 Drugs of Abuse / Toxicology In South Africa 202
8.10.1 Drugs of Abuse / Toxicology, South Africa, Overall Revenue (2003-2017) 202
8.11 Immuno Chemistry, South Africa, Distribution Share (2009-2010) 206
8.12 Immuno Chemistry, South Africa, Company Share (2009-2010) 207

9 Overview of Key Companies in BRICS Immuno Chemistry Market 209
9.1 Siemens Healthcare 209
9.1.1 Company Overview 209
9.1.2 Share in the BRICS Immuno Chemistry Market 210
9.2 F. Hoffmann-La Roche Ltd. 211
9.2.1 Company Overview 211
9.2.2 Share in the BRICS Immuno Chemistry Market 212
9.3 Abbott Laboratories 214
9.3.1 Company Overview 214
9.3.2 Share in the BRICS Immuno Chemistry Market 215
9.4 Ortho-Clinical Diagnostics Inc. 217
9.4.1 Company Overview 217
9.4.2 Share in the BRICS Immuno Chemistry Market 217
9.5 Beckman Coulter, Inc. 219
9.5.1 Company Overview 219
9.5.2 Share in the BRICS Immuno Chemistry Market 220
9.6 bioMerieux S.A. 222
9.6.1 Company Overview 222
9.6.2 Share in the BRICS Immuno Chemistry Market 223
9.7 Phadia AB 225
9.7.1 Company Overview 225
9.7.2 Share in the BRICS Immuno Chemistry Market 226
9.8 Alere Inc. 228
9.8.1 Company Overview 228
9.8.2 Share in the BRICS Immuno Chemistry Market 229
9.9 Bio-Rad Laboratories, Inc. 231
9.9.1 Company Overview 231
9.9.2 Share in the BRICS Immuno Chemistry Market 232
9.10 Transasia Bio-Medicals Ltd. 234
9.10.1 Company Overview 234
9.11 DiaSorin S.p.A 235
9.11.1 Company Overview 235
9.11.2 Share in the BRICS Immuno Chemistry Market 236
9.12 Danaher Corporation 238
9.12.1 Company Overview 238
9.13 PerkinElmer, Inc. 238
9.13.1 Company Overview 238
9.14 Trivitron Healthcare Pvt Ltd. 238
9.14.1 Company Overview 238
9.15 Span Diagnostics Ltd. 239
9.15.1 Company Overview 239
9.16 OLYMPUS CORPORATION 239
9.16.1 Company Overview 239

10 Appendix 240
10.1 Definitions of Markets Covered in the Report 241
10.1.1 Immuno Chemistry 241
10.2 Research Methodology 245
10.3 Secondary Research 245
10.4 Primary Research 246
10.5 Models 246
10.6 Forecasts 247
10.7 Expert Panels 247
10.8 GlobalData Consulting 247
10.9 Currency Conversion 248
10.10 Contact Us 248
10.11 Disclaimer 248

List of Tables

Table 1: Immuno Chemistry, BRICS, Overall Revenue ($m), 2003-2017 18
Table 2: Immuno Chemistry, BRICS, Overall Revenue ($m), Historic, 2003-2010 20
Table 3: Immuno Chemistry, BRICS, Overall Revenue ($m), Forecast, 2010-2017 22
Table 4: Immuno Chemistry, BRICS, Company share by Revenue ($m), USD Actual, 2009-2010 24
Table 5: Immuno Chemistry, Brazil, Overall Revenue ($m), USD Actual, 2003-2017 26
Table 6: Immuno Chemistry, Brazil, Overall Revenue ($m), USD Actual, Historic, 2003-2010 28
Table 7: Immuno Chemistry, Brazil, Overall Revenue ($m), USD Actual, Forecast, 2010-2017 30
Table 8: Disease Specific Immunochemistry, Brazil, Revenue ($m) by Segment, Historic, 2003-2010 32
Table 9: Disease Specific Immunochemistry, Brazil, Revenue ($m) by Segment, Forecast, 2010-2017 34
Table 10: Endocrinology Tests, Brazil, Revenue ($m) by Segment, Historic, 2003-2010 36
Table 11: Endocrinology Tests, Brazil, Revenue ($m) by Segment, Forecast, 2010-2017 37
Table 12: Organ Function Assays, Brazil, Revenue ($m), Historic, 2003-2010 38
Table 13: Organ Function Assays, Brazil, Revenue ($m), Forecast, 2010-2017 39
Table 14: Therapeutic Drug Monitoring, Brazil, Revenue ($m) by Segment, Historic, 2003-2010 41
Table 15: Therapeutic Drug Monitoring, Brazil, Revenue ($m) by Segment, Forecast, 2010-2017 43
Table 16: Immunochemistry Analyzers, Brazil, Revenue ($m) by Segment, Historic, 2003-2010 45
Table 17: Immunochemistry Analyzers, Brazil, Revenue ($m) by Segment, Forecast, 2010-2017 47
Table 18: Specific Proteins, Brazil, Revenue ($m), Historic, 2003-2010 48
Table 19: Specific Proteins, Brazil, Revenue ($m), Forecast, 2010-2017 49
Table 20: Anemia / Vitamin Tests, Brazil, Revenue ($m), Historic, 2003-2010 50
Table 21: Anemia / Vitamin Tests, Brazil, Revenue ($m), Forecast, 2010-2017 51
Table 22: Immunochemistry Rapid Tests, Brazil, Revenue ($m), Historic, 2003-2010 52
Table 23: Immunochemistry Rapid Tests, Brazil, Revenue ($m), Forecast, 2010-2017 53
Table 24: Drugs of Abuse / Toxicology, Brazil, Revenue ($m) by Segment, Historic, 2003-2010 55
Table 25: Drugs of Abuse / Toxicology, Brazil, Revenue ($m) by Segment, Forecast, 2010-2017 57
Table 26: Immuno Chemistry, Brazil, Distribution Share by Revenue ($m), USD Actual, 2009-2010 58
Table 27: Immuno Chemistry, Brazil, Company share by Revenue ($m), USD Actual, 2009-2010 60
Table 28: Immuno Chemistry, Russian Federation, Overall Revenue ($m), USD Actual, 2003-2017 62
Table 29: Immuno Chemistry, Russian Federation, Overall Revenue ($m), USD Actual, Historic, 2003-2010 64
Table 30: Immuno Chemistry, Russian Federation, Overall Revenue ($m), USD Actual, Forecast, 2010-2017 66
Table 31: Immunochemistry Analyzers, Russian Federation, Revenue ($m) by Segment, Historic, 2003-2010 68
Table 32: Immunochemistry Analyzers, Russian Federation, Revenue ($m) by Segment, Forecast, 2010-2017 70
Table 33: Endocrinology Tests, Russian Federation, Revenue ($m) by Segment, Historic, 2003-2010 72
Table 34: Endocrinology Tests, Russian Federation, Revenue ($m) by Segment, Forecast, 2010-2017 74
Table 35: Disease Specific Immunochemistry, Russian Federation, Revenue ($m) by Segment, Historic, 2003-2010 76
Table 36: Disease Specific Immunochemistry, Russian Federation, Revenue ($m) by Segment, Forecast, 2010-2017 78
Table 37: Organ Function Assays, Russian Federation, Revenue ($m), Historic, 2003-2010 79
Table 38: Organ Function Assays, Russian Federation, Revenue ($m), Forecast, 2010-2017 80
Table 39: Anemia / Vitamin Tests, Russian Federation, Revenue ($m), Historic, 2003-2010 81
Table 40: Anemia / Vitamin Tests, Russian Federation, Revenue ($m), Forecast, 2010-2017 82
Table 41: Specific Proteins, Russian Federation, Revenue ($m), Historic, 2003-2010 83
Table 42: Specific Proteins, Russian Federation, Revenue ($m), Forecast, 2010-2017 84
Table 43: Therapeutic Drug Monitoring, Russian Federation, Revenue ($m) by Segment, Historic, 2003-2010 86
Table 44: Therapeutic Drug Monitoring, Russian Federation, Revenue ($m) by Segment, Forecast, 2010-2017 88
Table 45: Drugs of Abuse / Toxicology, Russian Federation, Revenue ($m) by Segment, Historic, 2003-2010 90
Table 46: Drugs of Abuse / Toxicology, Russian Federation, Revenue ($m) by Segment, Forecast, 2010-2017 92
Table 47: Immunochemistry Rapid Tests, Russian Federation, Revenue ($m), Historic, 2003-2010 93
Table 48: Immunochemistry Rapid Tests, Russian Federation, Revenue ($m), Forecast, 2010-2017 94
Table 49: Immuno Chemistry, Russian Federation, Distribution Share by Revenue ($m), USD Actual, 2009-2010 95
Table 50: Immuno Chemistry, Russian Federation, Company share by Revenue ($m), USD Actual, 2009-2010 97
Table 51: Immuno Chemistry, India, Overall Revenue ($m), USD Actual, 2003-2017 99
Table 52: Immuno Chemistry, India, Overall Revenue ($m), USD Actual, Historic, 2003-2010 101
Table 53: Immuno Chemistry, India, Overall Revenue ($m), USD Actual, Forecast, 2010-2017 103
Table 54: Endocrinology Tests, India, Revenue ($m) by Segment, Historic, 2003-2010 105
Table 55: Endocrinology Tests, India, Revenue ($m) by Segment, Forecast, 2010-2017 107
Table 56: Immunochemistry Rapid Tests, India, Revenue ($m), Historic, 2003-2010 108
Table 57: Immunochemistry Rapid Tests, India, Revenue ($m), Forecast, 2010-2017 109
Table 58: Immunochemistry Analyzers, India, Revenue ($m) by Segment, Historic, 2003-2010 111
Table 59: Immunochemistry Analyzers, India, Revenue ($m) by Segment, Forecast, 2010-2017 113
Table 60: Disease Specific Immunochemistry, India, Revenue ($m) by Segment, Historic, 2003-2010 115
Table 61: Disease Specific Immunochemistry, India, Revenue ($m) by Segment, Forecast, 2010-2017 117
Table 62: Organ Function Assays, India, Revenue ($m), Historic, 2003-2010 118
Table 63: Organ Function Assays, India, Revenue ($m), Forecast, 2010-2017 119
Table 64: Anemia / Vitamin Tests, India, Revenue ($m), Historic, 2003-2010 120
Table 65: Anemia / Vitamin Tests, India, Revenue ($m), Forecast, 2010-2017 121
Table 66: Drugs of Abuse / Toxicology, India, Revenue ($m) by Segment, Historic, 2003-2010 123
Table 67: Drugs of Abuse / Toxicology, India, Revenue ($m) by Segment, Forecast, 2010-2017 125
Table 68: Specific Proteins, India, Revenue ($m), Historic, 2003-2010 126
Table 69: Specific Proteins, India, Revenue ($m), Forecast, 2010-2017 127
Table 70: Therapeutic Drug Monitoring, India, Revenue ($m) by Segment, Historic, 2003-2010 129
Table 71: Therapeutic Drug Monitoring, India, Revenue ($m) by Segment, Forecast, 2010-2017 131
Table 72: Immuno Chemistry, India, Distribution Share by Revenue ($m), USD Actual, 2009-2010 132
Table 73: Immuno Chemistry, India, Company share by Revenue ($m), USD Actual, 2009-2010 134
Table 74: Immuno Chemistry, China, Overall Revenue ($m), USD Actual, 2003-2017 136
Table 75: Immuno Chemistry, China, Overall Revenue ($m), USD Actual, Historic, 2003-2010 138
Table 76: Immuno Chemistry, China, Overall Revenue ($m), USD Actual, Forecast, 2010-2017 140
Table 77: Disease Specific Immunochemistry, China, Revenue ($m) by Segment, Historic, 2003-2010 142
Table 78: Disease Specific Immunochemistry, China, Revenue ($m) by Segment, Forecast, 2010-2017 144
Table 79: Immunochemistry Rapid Tests, China, Revenue ($m), Historic, 2003-2010 145
Table 80: Immunochemistry Rapid Tests, China, Revenue ($m), Forecast, 2010-2017 146
Table 81: Endocrinology Tests, China, Revenue ($m) by Segment, Historic, 2003-2010 148
Table 82: Endocrinology Tests, China, Revenue ($m) by Segment, Forecast, 2010-2017 150
Table 83: Immunochemistry Analyzers, China, Revenue ($m) by Segment, Historic, 2003-2010 152
Table 84: Immunochemistry Analyzers, China, Revenue ($m) by Segment, Forecast, 2010-2017 154
Table 85: Organ Function Assays, China, Revenue ($m), Historic, 2003-2010 155
Table 86: Organ Function Assays, China, Revenue ($m), Forecast, 2010-2017 156
Table 87: Anemia / Vitamin Tests, China, Revenue ($m), Historic, 2003-2010 157
Table 88: Anemia / Vitamin Tests, China, Revenue ($m), Forecast, 2010-2017 158
Table 89: Specific Proteins, China, Revenue ($m), Historic, 2003-2010 159
Table 90: Specific Proteins, China, Revenue ($m), Forecast, 2010-2017 160
Table 91: Therapeutic Drug Monitoring, China, Revenue ($m) by Segment, Historic, 2003-2010 162
Table 92: Therapeutic Drug Monitoring, China, Revenue ($m) by Segment, Forecast, 2010-2017 164
Table 93: Drugs of Abuse / Toxicology, China, Revenue ($m) by Segment, Historic, 2003-2010 166
Table 94: Drugs of Abuse / Toxicology, China, Revenue ($m) by Segment, Forecast, 2010-2017 168
Table 95: Immuno Chemistry, China, Distribution Share by Revenue ($m), USD Actual, 2009-2010 169
Table 96: Immuno Chemistry, China, Company share by Revenue ($m), USD Actual, 2009-2010 171
Table 97: Immuno Chemistry, South Africa, Overall Revenue ($m), USD Actual, 2003-2017 173
Table 98: Immuno Chemistry, South Africa, Overall Revenue ($m), USD Actual, Historic, 2003-2010 175
Table 99: Immuno Chemistry, South Africa, Overall Revenue ($m), USD Actual, Forecast, 2010-2017 177
Table 100: Disease Specific Immunochemistry, South Africa, Revenue ($m) by Segment, Historic, 2003-2010 179
Table 101: Disease Specific Immunochemistry, South Africa, Revenue ($m) by Segment, Forecast, 2010-2017 181
Table 102: Immunochemistry Analyzers, South Africa, Revenue ($m) by Segment, Historic, 2003-2010 183
Table 103: Immunochemistry Analyzers, South Africa, Revenue ($m) by Segment, Forecast, 2010-2017 185
Table 104: Organ Function Assays, South Africa, Revenue ($m), Historic, 2003-2010 186
Table 105: Organ Function Assays, South Africa, Revenue ($m), Forecast, 2010-2017 187
Table 106: Endocrinology Tests, South Africa, Revenue ($m) by Segment, Historic, 2003-2010 189
Table 107: Endocrinology Tests, South Africa, Revenue ($m) by Segment, Forecast, 2010-2017 191
Table 108: Immunochemistry Rapid Tests, South Africa, Revenue ($m), Historic, 2003-2010 192
Table 109: Immunochemistry Rapid Tests, South Africa, Revenue ($m), Forecast, 2010-2017 193
Table 110: Specific Proteins, South Africa, Revenue ($m), Historic, 2003-2010 194
Table 111: Specific Proteins, South Africa, Revenue ($m), Forecast, 2010-2017 195
Table 112: Therapeutic Drug Monitoring, South Africa, Revenue ($m) by Segment, Historic, 2003-2010 197
Table 113: Therapeutic Drug Monitoring, South Africa, Revenue ($m) by Segment, Forecast, 2010-2017 199
Table 114: Anemia / Vitamin Tests, South Africa, Revenue ($m), Historic, 2003-2010 200
Table 115: Anemia / Vitamin Tests, South Africa, Revenue ($m), Forecast, 2010-2017 201
Table 116: Drugs of Abuse / Toxicology, South Africa, Revenue ($m) by Segment, Historic, 2003-2010 203
Table 117: Drugs of Abuse / Toxicology, South Africa, Revenue ($m) by Segment, Forecast, 2010-2017 205
Table 118: Immuno Chemistry, South Africa, Distribution Share by Revenue ($m), USD Actual, 2009-2010 206
Table 119: Immuno Chemistry, South Africa, Company share by Revenue ($m), USD Actual, 2009-2010 208
Table 120: Siemens Healthcare, Revenue ($m), BRICS Immuno Chemistry Market, 2010 210
Table 121: F. Hoffmann-La Roche Ltd., Revenue ($m), BRICS Immuno Chemistry Market, 2010 213
Table 122: Abbott Laboratories, Revenue ($m), BRICS Immuno Chemistry Market, 2010 216
Table 123: Ortho-Clinical Diagnostics Inc., Revenue ($m), BRICS Immuno Chemistry Market, 2010 218
Table 124: Beckman Coulter, Inc., Revenue ($m), BRICS Immuno Chemistry Market, 2010 221
Table 125: bioMerieux S.A., Revenue ($m), BRICS Immuno Chemistry Market, 2010 224
Table 126: Phadia AB, Revenue ($m), BRICS Immuno Chemistry Market, 2010 227
Table 127: Alere Inc., Revenue ($m), BRICS Immuno Chemistry Market, 2010 230
Table 128: Bio-Rad Laboratories, Inc., Revenue ($m), BRICS Immuno Chemistry Market, 2010 233
Table 129: Transasia Bio-Medicals Ltd., Revenue ($m), BRICS Immuno Chemistry Market, 2010 234
Table 130: DiaSorin S.p.A, Revenue ($m), BRICS Immuno Chemistry Market, 2010 237
Table 131: USD to Local Currency, BRICS, Average Exchange Rate, 2003-2010 248

List of Figures

Figure 1: Immuno Chemistry, BRICS, Overall Revenue ($m), 2003-2017 17
Figure 2: Immuno Chemistry, BRICS, Overall Revenue ($m), Historic, 2003-2010 19
Figure 3: Immuno Chemistry, BRICS, Overall Revenue ($m), Forecast, 2010-2017 21
Figure 4: Immuno Chemistry, BRICS, Company share (%), 2010 23
Figure 5: Immuno Chemistry, Brazil, Overall Revenue ($m), USD Actual, 2003-2017 25
Figure 6: Immuno Chemistry, Brazil, Overall Revenue ($m), USD Actual, Historic, 2003-2010 27
Figure 7: Immuno Chemistry, Brazil, Overall Revenue ($m), USD Actual, Forecast, 2010-2017 29
Figure 8: Disease Specific Immunochemistry, Brazil, Revenue ($m) by Segment, Historic, 2003-2010 31
Figure 9: Disease Specific Immunochemistry, Brazil, Revenue ($m) by Segment, Forecast, 2010-2017 33
Figure 10: Endocrinology Tests, Brazil, Revenue ($m) by Segment, Historic, 2003-2010 35
Figure 11: Endocrinology Tests, Brazil, Revenue ($m) by Segment, Forecast, 2010-2017 37
Figure 12: Organ Function Assays, Brazil, Revenue ($m), Historic, 2003-2010 38
Figure 13: Organ Function Assays, Brazil, Revenue ($m), Forecast, 2010-2017 39
Figure 14: Therapeutic Drug Monitoring, Brazil, Revenue ($m) by Segment, Historic, 2003-2010 40
Figure 15: Therapeutic Drug Monitoring, Brazil, Revenue ($m) by Segment, Forecast, 2010-2017 42
Figure 16: Immunochemistry Analyzers, Brazil, Revenue ($m) by Segment, Historic, 2003-2010 44
Figure 17: Immunochemistry Analyzers, Brazil, Revenue ($m) by Segment, Forecast, 2010-2017 46
Figure 18: Specific Proteins, Brazil, Revenue ($m), Historic, 2003-2010 48
Figure 19: Specific Proteins, Brazil, Revenue ($m), Forecast, 2010-2017 49
Figure 20: Anemia / Vitamin Tests, Brazil, Revenue ($m), Historic, 2003-2010 50
Figure 21: Anemia / Vitamin Tests, Brazil, Revenue ($m), Forecast, 2010-2017 51
Figure 22: Immunochemistry Rapid Tests, Brazil, Revenue ($m), Historic, 2003-2010 52
Figure 23: Immunochemistry Rapid Tests, Brazil, Revenue ($m), Forecast, 2010-2017 53
Figure 24: Drugs of Abuse / Toxicology, Brazil, Revenue ($m) by Segment, Historic, 2003-2010 54
Figure 25: Drugs of Abuse / Toxicology, Brazil, Revenue ($m) by Segment, Forecast, 2010-2017 56
Figure 26: Immuno Chemistry, Brazil, Company share (%), 2010 59
Figure 27: Immuno Chemistry, Russian Federation, Overall Revenue ($m), USD Actual, 2003-2017 61
Figure 28: Immuno Chemistry, Russian Federation, Overall Revenue ($m), USD Actual, Historic, 2003-2010 63
Figure 29: Immuno Chemistry, Russian Federation, Overall Revenue ($m), USD Actual, Forecast, 2010-2017 65
Figure 30: Immunochemistry Analyzers, Russian Federation, Revenue ($m) by Segment, Historic, 2003-2010 67
Figure 31: Immunochemistry Analyzers, Russian Federation, Revenue ($m) by Segment, Forecast, 2010-2017 69
Figure 32: Endocrinology Tests, Russian Federation, Revenue ($m) by Segment, Historic, 2003-2010 71
Figure 33: Endocrinology Tests, Russian Federation, Revenue ($m) by Segment, Forecast, 2010-2017 73
Figure 34: Disease Specific Immunochemistry, Russian Federation, Revenue ($m) by Segment, Historic, 2003-2010 75
Figure 35: Disease Specific Immunochemistry, Russian Federation, Revenue ($m) by Segment, Forecast, 2010-2017 77
Figure 36: Organ Function Assays, Russian Federation, Revenue ($m), Historic, 2003-2010 79
Figure 37: Organ Function Assays, Russian Federation, Revenue ($m), Forecast, 2010-2017 80
Figure 38: Anemia / Vitamin Tests, Russian Federation, Revenue ($m), Historic, 2003-2010 81
Figure 39: Anemia / Vitamin Tests, Russian Federation, Revenue ($m), Forecast, 2010-2017 82
Figure 40: Specific Proteins, Russian Federation, Revenue ($m), Historic, 2003-2010 83
Figure 41: Specific Proteins, Russian Federation, Revenue ($m), Forecast, 2010-2017 84
Figure 42: Therapeutic Drug Monitoring, Russian Federation, Revenue ($m) by Segment, Historic, 2003-2010 85
Figure 43: Therapeutic Drug Monitoring, Russian Federation, Revenue ($m) by Segment, Forecast, 2010-2017 87
Figure 44: Drugs of Abuse / Toxicology, Russian Federation, Revenue ($m) by Segment, Historic, 2003-2010 89
Figure 45: Drugs of Abuse / Toxicology, Russian Federation, Revenue ($m) by Segment, Forecast, 2010-2017 91
Figure 46: Immunochemistry Rapid Tests, Russian Federation, Revenue ($m), Historic, 2003-2010 93
Figure 47: Immunochemistry Rapid Tests, Russian Federation, Revenue ($m), Forecast, 2010-2017 94
Figure 48: Immuno Chemistry, Russian Federation, Company share (%), 2010 96
Figure 49: Immuno Chemistry, India, Overall Revenue ($m), USD Actual, 2003-2017 98
Figure 50: Immuno Chemistry, India, Overall Revenue ($m), USD Actual, Historic, 2003-2010 100
Figure 51: Immuno Chemistry, India, Overall Revenue ($m), USD Actual, Forecast, 2010-2017 102
Figure 52: Endocrinology Tests, India, Revenue ($m) by Segment, Historic, 2003-2010 104
Figure 53: Endocrinology Tests, India, Revenue ($m) by Segment, Forecast, 2010-2017 106
Figure 54: Immunochemistry Rapid Tests, India, Revenue ($m), Historic, 2003-2010 108
Figure 55: Immunochemistry Rapid Tests, India, Revenue ($m), Forecast, 2010-2017 109
Figure 56: Immunochemistry Analyzers, India, Revenue ($m) by Segment, Historic, 2003-2010 110
Figure 57: Immunochemistry Analyzers, India, Revenue ($m) by Segment, Forecast, 2010-2017 112
Figure 58: Disease Specific Immunochemistry, India, Revenue ($m) by Segment, Historic, 2003-2010 114
Figure 59: Disease Specific Immunochemistry, India, Revenue ($m) by Segment, Forecast, 2010-2017 116
Figure 60: Organ Function Assays, India, Revenue ($m), Historic, 2003-2010 118
Figure 61: Organ Function Assays, India, Revenue ($m), Forecast, 2010-2017 119
Figure 62: Anemia / Vitamin Tests, India, Revenue ($m), Historic, 2003-2010 120
Figure 63: Anemia / Vitamin Tests, India, Revenue ($m), Forecast, 2010-2017 121
Figure 64: Drugs of Abuse / Toxicology, India, Revenue ($m) by Segment, Historic, 2003-2010 122
Figure 65: Drugs of Abuse / Toxicology, India, Revenue ($m) by Segment, Forecast, 2010-2017 124
Figure 66: Specific Proteins, India, Revenue ($m), Historic, 2003-2010 126
Figure 67: Specific Proteins, India, Revenue ($m), Forecast, 2010-2017 127
Figure 68: Therapeutic Drug Monitoring, India, Revenue ($m) by Segment, Historic, 2003-2010 128
Figure 69: Therapeutic Drug Monitoring, India, Revenue ($m) by Segment, Forecast, 2010-2017 130
Figure 70: Immuno Chemistry, India, Company share (%), 2010 133
Figure 71: Immuno Chemistry, China, Overall Revenue ($m), USD Actual, 2003-2017 135
Figure 72: Immuno Chemistry, China, Overall Revenue ($m), USD Actual, Historic, 2003-2010 137
Figure 73: Immuno Chemistry, China, Overall Revenue ($m), USD Actual, Forecast, 2010-2017 139
Figure 74: Disease Specific Immunochemistry, China, Revenue ($m) by Segment, Historic, 2003-2010 141
Figure 75: Disease Specific Immunochemistry, China, Revenue ($m) by Segment, Forecast, 2010-2017 143
Figure 76: Immunochemistry Rapid Tests, China, Revenue ($m), Historic, 2003-2010 145
Figure 77: Immunochemistry Rapid Tests, China, Revenue ($m), Forecast, 2010-2017 146
Figure 78: Endocrinology Tests, China, Revenue ($m) by Segment, Historic, 2003-2010 147
Figure 79: Endocrinology Tests, China, Revenue ($m) by Segment, Forecast, 2010-2017 149
Figure 80: Immunochemistry Analyzers, China, Revenue ($m) by Segment, Historic, 2003-2010 151
Figure 81: Immunochemistry Analyzers, China, Revenue ($m) by Segment, Forecast, 2010-2017 153
Figure 82: Organ Function Assays, China, Revenue ($m), Historic, 2003-2010 155
Figure 83: Organ Function Assays, China, Revenue ($m), Forecast, 2010-2017 156
Figure 84: Anemia / Vitamin Tests, China, Revenue ($m), Historic, 2003-2010 157
Figure 85: Anemia / Vitamin Tests, China, Revenue ($m), Forecast, 2010-2017 158
Figure 86: Specific Proteins, China, Revenue ($m), Historic, 2003-2010 159
Figure 87: Specific Proteins, China, Revenue ($m), Forecast, 2010-2017 160
Figure 88: Therapeutic Drug Monitoring, China, Revenue ($m) by Segment, Historic, 2003-2010 161
Figure 89: Therapeutic Drug Monitoring, China, Revenue ($m) by Segment, Forecast, 2010-2017 163
Figure 90: Drugs of Abuse / Toxicology, China, Revenue ($m) by Segment, Historic, 2003-2010 165
Figure 91: Drugs of Abuse / Toxicology, China, Revenue ($m) by Segment, Forecast, 2010-2017 167
Figure 92: Immuno Chemistry, China, Company share (%), 2010 170
Figure 93: Immuno Chemistry, South Africa, Overall Revenue ($m), USD Actual, 2003-2017 172
Figure 94: Immuno Chemistry, South Africa, Overall Revenue ($m), USD Actual, Historic, 2003-2010 174
Figure 95: Immuno Chemistry, South Africa, Overall Revenue ($m), USD Actual, Forecast, 2010-2017 176
Figure 96: Disease Specific Immunochemistry, South Africa, Revenue ($m) by Segment, Historic, 2003-2010 178
Figure 97: Disease Specific Immunochemistry, South Africa, Revenue ($m) by Segment, Forecast, 2010-2017 180
Figure 98: Immunochemistry Analyzers, South Africa, Revenue ($m) by Segment, Historic, 2003-2010 182
Figure 99: Immunochemistry Analyzers, South Africa, Revenue ($m) by Segment, Forecast, 2010-2017 184
Figure 100: Organ Function Assays, South Africa, Revenue ($m), Historic, 2003-2010 186
Figure 101: Organ Function Assays, South Africa, Revenue ($m), Forecast, 2010-2017 187
Figure 102: Endocrinology Tests, South Africa, Revenue ($m) by Segment, Historic, 2003-2010 188
Figure 103: Endocrinology Tests, South Africa, Revenue ($m) by Segment, Forecast, 2010-2017 190
Figure 104: Immunochemistry Rapid Tests, South Africa, Revenue ($m), Historic, 2003-2010 192
Figure 105: Immunochemistry Rapid Tests, South Africa, Revenue ($m), Forecast, 2010-2017 193
Figure 106: Specific Proteins, South Africa, Revenue ($m), Historic, 2003-2010 194
Figure 107: Specific Proteins, South Africa, Revenue ($m), Forecast, 2010-2017 195
Figure 108: Therapeutic Drug Monitoring, South Africa, Revenue ($m) by Segment, Historic, 2003-2010 196
Figure 109: Therapeutic Drug Monitoring, South Africa, Revenue ($m) by Segment, Forecast, 2010-2017 198
Figure 110: Anemia / Vitamin Tests, South Africa, Revenue ($m), Historic, 2003-2010 200
Figure 111: Anemia / Vitamin Tests, South Africa, Revenue ($m), Forecast, 2010-2017 201
Figure 112: Drugs of Abuse / Toxicology, South Africa, Revenue ($m) by Segment, Historic, 2003-2010 202
Figure 113: Drugs of Abuse / Toxicology, South Africa, Revenue ($m) by Segment, Forecast, 2010-2017 204
Figure 114: Immuno Chemistry, South Africa, Company share (%), 2010 207
Figure 115: Siemens Healthcare, Company Share (%), BRICS Immuno Chemistry Market, 2010 210
Figure 116: F. Hoffmann-La Roche Ltd., Company Share (%), BRICS Immuno Chemistry Market, 2010 212
Figure 117: Abbott Laboratories, Company Share (%), BRICS Immuno Chemistry Market, 2010 215
Figure 118: Ortho-Clinical Diagnostics Inc., Company Share (%), BRICS Immuno Chemistry Market, 2